Trichuris suis secrete products that reduce disease severity in a multiple sclerosis model

2017 ◽  
Vol 62 (1) ◽  
Author(s):  
Christine Søholm Hansen ◽  
Henrik Hasseldam ◽  
Idahella Hyldgaard Bacher ◽  
Stig Milan Thamsborg ◽  
Flemming Fryd Johansen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Disease Severity ◽  
Western World ◽  
Cns Disease ◽  
High Prevalence ◽  
High Level ◽  
Reduce Disease Severity ◽  
Multiple Sclerosis Model

AbstractMultiple sclerosis is a chronic inflammatory central nervous system (CNS) disease, which affects about 1 in 1000 individuals in the western world. It has been suggested that this relatively high prevalence is linked to a high level of hygiene,

scholarly journals Fatigue and Affective Manifestations in Multiple Sclerosis—A Cluster Approach

2019 ◽  
Vol 10 (1) ◽  
pp. 10 ◽  
Author(s):  
Samar S. Ayache ◽  
Moussa A. Chalah
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Economic Cost ◽  
Cluster Approach ◽  
High Prevalence ◽  
The Central Nervous System ◽  
Chronic Autoimmune Disease

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, characterized by a high prevalence in young people, a drastic impact on the quality of life, and an important economic cost to society [...]

Non–Multiple Sclerosis Central Nervous System Inflammatory Disease

2021 ◽  
pp. 555-564
Author(s):  
Nicholas L. Zalewski ◽  
Sean J. Pittock
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Inflammatory Disease ◽  
Inflammatory Diseases ◽  
Cns Disease

Multiple sclerosis (MS) is the most common inflammatory central nervous system (CNS) disease. Yet, clinicians should be cognizant of other demyelinating and nondemyelinating CNS inflammatory diseases, some of which mimic MS. This chapter reviews the spectrum of non-MS CNS inflammatory diseases and MS mimics.

Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB 1 cannabinoid receptor agonists

2013 ◽  
Vol 28 (1) ◽  
pp. 117-130 ◽  
Author(s):  
Gareth Pryce ◽  
Cristina Visintin ◽  
Sreeram V. Ramagopalan ◽  
Sarah Al‐Izki ◽  
Lia E. De Faveri ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Cannabinoid Receptor ◽  
Receptor Agonists ◽  
Multiple Sclerosis Model

scholarly journals GCT-10. CAN HIGH LEVEL SERUM hCG-β BE CONSIDERED EQUIVALENT TO A DIAGNOSIS OF CHORIOCARCINOMA IN PRIMARY CENTRAL NERVOUS SYSTEM GERM-CELL TUMOR?

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii329-iii330
Author(s):  
Hiroaki Motegi ◽  
Shigeru Yamaguchi ◽  
Yukitomo Ishi ◽  
Michinari Okamoto ◽  
Akihiro Iguchi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Good Prognosis ◽  
Cell Tumor ◽  
University Hospital ◽  
Kaplan Meier ◽  
Beta Human Chorionic Gonadotropin ◽  
High Level

Abstract BACKGROUND Primary central nervous system(CNS) choriocarcinoma(CC) is very rare and has the poorest prognosis among germ cell tumor (GCT). CC usually has extremely high level (HL) of serum beta-human chorionic gonadotropin (bhCG) over than 1,000 mIU/ml. Some studies assign HL bhCG cases to poor prognosis group even without biopsy. The purpose of this study was to find out if there was a good prognosis subset in the HL bh group. MATERIALS AND METHODS We analyzed 103 cases diagnosed with GCT from 1998 to 2019 in Hokkaido University Hospital and reviewed the literature of CNS CC and bhCG. Survival was assessed using Kaplan-Meier method and log-rank statistics between the group with CC component and that with no CC component but HL bhCG. RESULTS One out of 103 our cases was diagnosed as a mixed GCT with CC component and did not respond to treatment and died 9 months later. Two cases were treated as CC because of HL bhCG (1,226 and 2,739 mIU/ml) despite that the biopsy showed only germinomas and survived(105 and 37 months), that is, no CC component. Combining our cases with 69 cases in the literature, all 7 cases with no CC component but HL bhCG survived but the median survival of the other 65 cases with CC component was 38.2 months (P=0.02). CONCLUSION This study has a limitation of selection bias, however, it suggests that patients with no CC component but HL bhCG may have a better prognosis.

Multiple Sclerosis Is Rare in Epstein–Barr Virus–Seronegative Children with Central Nervous System Inflammatory Demyelination

2021 ◽  
Author(s):  
Bardia Nourbakhsh ◽  
Christian Cordano ◽  
Carlo Asteggiano ◽  
Klemens Ruprecht ◽  
Carolin Otto ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr
Sign in / Sign up

Export Citation Format

Share Document